Arginine

Arginine

SCHEMBL333332

C[C@@H](OC(=O)CN)[C@H](N)C(=O)O.N=C(N)NCCC[C@H](N)C(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OTC P00480 1/20 0.39
NOS1 P29475 6/20 0.38
NOS2 P35228 6/20 0.38
NOS3 P29474 5/20 0.38
DDAH1 O94760 4/20 0.38
GSR P00390 1/20 0.36
MEN1 O00255 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
NPY4R P50391 4/20 0.34
NPY1R P25929 3/20 0.34
NPY2R P49146 2/20 0.33
NPY5R Q15761 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
NOD1 Q9Y239 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Arginine SCHEMBL904454 0.88 OTC (0.41) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL6130138 0.85 GSR (0.46) OTCNOS1NOS2NOS3DDAH1
SCHEMBL1965668 0.85 NPY4R (0.38) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL27983903 0.82 OTC (0.43) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL28224090 0.82 OTC (0.43) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL10876829 0.82 GSR (0.43) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL25212883 0.82 OTC (0.47) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL4586460 0.82 OTC (0.47) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL4586458 0.82 OTC (0.47) OTCNOS1NOS2NOS3DDAH1
Arginine SCHEMBL2762369 0.81 OTC (0.42) OTCNOS1NOS2NOS3DDAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846866-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-30 US claimed
US-20130203111-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-08-08 US claimed
US-20210024614-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-01-28 US disclosed
US-10745464-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-08-18 US disclosed
US-20190153070-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-05-23 US disclosed
US-10150806-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-12-11 US disclosed
US-20170121389-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-04 US disclosed
EP-2548967-B1 Aldehyde tags, uses thereof in site-specific protein modification UNIV CALIFORNIA (US) 2016-12-28 EP disclosed
US-9447390-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-09-20 US disclosed
US-20150072398-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-03-12 US disclosed
US-8846866-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-30 US disclosed
US-8097701-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-17 US disclosed
US-20110287041-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-11-24 US disclosed
US-20110250704-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-10-13 US disclosed
US-7985783-B2 Aldehyde tags, uses thereof in site-specific protein modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-07-26 US disclosed
US-20110117621-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2011-05-19 US disclosed
WO-2009120611-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-10-01 WO disclosed
EP-2064334-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION The Regents of the University of California (US) 2009-06-03 EP disclosed
US-20080187956-A1 Modification at sulfatase motif of aldehyde tag through action of a formylglycine generating enzyme (FGE) generates formylglycine (FGly) residue NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2008-08-07 US disclosed
WO-2008036350-A2 ALDEHYDE TAGS, USES THEREOF IN SITE-SPECIFIC PROTEIN MODIFICATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203111-A1 Aldehyde Tags, Uses Thereof in Site-Specific Protein Modification PFAS, DNPEP, ANPEP OTC 1609/4885NOS1 4088/4885NOS2 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.